ADVN BIOMARKER STUDY

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The Atopic Dermatitis and Vaccinia Network (ADVN), funded by the National Institutes of Health, consists of a group of academic medical centers that will perform clinical research studies with the overall goal to make smallpox vaccines safer for the millions of people with atopic dermatitis (AD). People who have AD or who have outgrown AD often get skin infections. These can include such viral infections as herpes, molluscum contagiosum and eczema vaccinatum. Eczema vaccinatum is a severe and sometimes fatal skin infection caused by exposure to smallpox vaccine. Before 1972 people in the US were routinely given this vaccine but because this disease (smallpox) has been controlled, vaccinations are no longer given as part of routine care of children. Now, however, an epidemic of smallpox caused by a bioterrorist act could make smallpox vaccinations necessary. The mission of the ADVN is to understand why patients who have AD, or who have had it in the past, are prone to increased skin infections and to find safer ways to protect them and their families from the possibility of smallpox. The ADVN Biomarker Registry Study is just one of the studies being done by the ADVN. The Primary Objective of this study is collecting information about subjects who have eczema, eczema herpeticum, eczema vaccinatum, eczema with molluscum contagiosum, molluscum contagiosum, and normal, healthy subjects. Another objective of the Registry/Biomarkers study is to assess the relationship between various biomarkers and subject characteristics. Blood samples will be taken from about 1,000 study volunteers at 5 different medical centers. ADVN investigators plan to study at least 185 blood samples each year from all centers. National Jewish Medical and Research Center will enroll approximately 200 subjects (50 per year).